Literature DB >> 16199530

Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein.

Jie Tang1, Christine Luong Yu, Steven R Williams, Eric Springman, Douglas Jeffery, Paul A Sprengeler, Alberto Estevez, Jun Sampang, William Shrader, Jeff Spencer, Wendy Young, Mary McGrath, Bradley A Katz.   

Abstract

Plasma kallikrein is a serine protease that has many important functions, including modulation of blood pressure, complement activation, and mediation and maintenance of inflammatory responses. Although plasma kallikrein has been purified for 40 years, its structure has not been elucidated. In this report, we described two systems (Pichia pastoris and baculovirus/Sf9 cells) for expression of the protease domain of plasma kallikrein, along with the purification and high resolution crystal structures of the two recombinant forms. In the Pichia pastoris system, the protease domain was expressed as a heterogeneously glycosylated zymogen that was activated by limited trypsin digestion and treated with endoglycosidase H deglycosidase to reduce heterogeneity from the glycosylation. The resulting protein was chromatographically resolved into four components, one of which was crystallized. In the baculovirus/Sf9 system, homogeneous, crystallizable, and nonglycosylated protein was expressed after mutagenizing three asparagines (the glycosylation sites) to glutamates. When assayed against the peptide substrates, pefachrome-PK and oxidized insulin B chain, both forms of the protease domain were found to have catalytic activity similar to that of the full-length protein. Crystallization and x-ray crystal structure determination of both forms have yielded the first three-dimensional views of the catalytic domain of plasma kallikrein. The structures, determined at 1.85 A for the endoglycosidase H-deglycosylated protease domain produced from P. pastoris and at 1.40 A for the mutagenically deglycosylated form produced from Sf9 cells, show that the protease domain adopts a typical chymotrypsin-like serine protease conformation. The structural information provides insights into the biochemical and enzymatic properties of plasma kallikrein and paves the way for structure-based design of protease inhibitors that are selective either for or against plasma kallikrein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16199530     DOI: 10.1074/jbc.M506766200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Preliminary X-ray crystallographic analysis of the catalytic domain of prophenoloxidase activating factor-I.

Authors:  Shunfu Piao; Ji Young Jung; Ji Won Park; Jaewon Lee; Bok Leul Lee; Nam Chul Ha
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-07-24

Review 2.  The expanding diversity of serine hydrolases.

Authors:  Istvan Botos; Alexander Wlodawer
Journal:  Curr Opin Struct Biol       Date:  2007-09-24       Impact factor: 6.809

3.  Structures of human plasma β-factor XIIa cocrystallized with potent inhibitors.

Authors:  Alexey Dementiev; Abel Silva; Calvin Yee; Zhe Li; Michael T Flavin; Hing Sham; James R Partridge
Journal:  Blood Adv       Date:  2018-03-13

4.  Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant.

Authors:  Madhu S Bajaj; Godwin I Ogueli; Yogesh Kumar; Kanagasabai Vadivel; Gregory Lawson; Sreejesh Shanker; Amy E Schmidt; S Paul Bajaj
Journal:  J Biol Chem       Date:  2010-11-29       Impact factor: 5.157

5.  Active site conformational changes of prostasin provide a new mechanism of protease regulation by divalent cations.

Authors:  Glen Spraggon; Michael Hornsby; Aaron Shipway; David C Tully; Badry Bursulaya; Henry Danahay; Jennifer L Harris; Scott A Lesley
Journal:  Protein Sci       Date:  2009-05       Impact factor: 6.725

6.  Structure of human prostasin, a target for the regulation of hypertension.

Authors:  Keith W Rickert; Paul Kelley; Noel J Byrne; Ronald E Diehl; Dawn L Hall; Allison M Montalvo; John C Reid; Jennifer M Shipman; Bradley W Thomas; Sanjeev K Munshi; Paul L Darke; Hua-Poo Su
Journal:  J Biol Chem       Date:  2008-10-14       Impact factor: 5.157

Review 7.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

8.  A disease-causing novel missense mutation in the ST14 gene underlies autosomal recessive ichthyosis with hypotrichosis syndrome in a consanguineous family.

Authors:  Farooq Ahmad; Ishtaiq Ahmed; Abdul Nasir; Muhammad Umair; Shaheen Shahzad; Dost Muhammad; Regie Lyn P Santos-Cortez; Suzanne M Leal; Wasim Ahmad
Journal:  Eur J Dermatol       Date:  2018-04-01       Impact factor: 3.328

9.  Structure of BbKI, a disulfide-free plasma kallikrein inhibitor.

Authors:  Dongwen Zhou; Daiane Hansen; Ivan G Shabalin; Alla Gustchina; Debora F Vieira; Marlon V de Brito; Ana Paula U Araújo; Maria Luiza V Oliva; Alexander Wlodawer
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-07-29       Impact factor: 1.056

10.  Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.

Authors:  Peng Xu; Mingming Xu; Longguang Jiang; Qinglan Yang; Zhipu Luo; Zbigniew Dauter; Mingdong Huang; Peter A Andreasen
Journal:  J Med Chem       Date:  2015-11-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.